
Rossari Biotech Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- The company expects low to mid double-digit top-line growth, aiming for around 12%-13% revenue growth for the full year FY25 (Page 9, Page 12).
- Export sales are a key growth driver, having grown 32% in H1 FY25 and currently constituting about 25% of overall sales. Exports are expected to outpace domestic growth further (Page 3, Page 9).
- Volume growth is expected in the Textile segment domestically (~6%-7% YoY growth) despite pricing pressure (Page 5).
- Animal Health & Nutrition business anticipates a much stronger second half, with Q3 and Q4 traditionally being strong quarters, aided by new products and infrastructure improvements (Page 6, Page 11).
- New capacities coming online in the next 3-4 months and ongoing CAPEX projects will enhance production, aiming for asset turns of 3x-4x (Page 11, Page 12).
- Improvement in margin and utilization expected as new products and capacities scale up (Page 12).
See what Rossari Biotech management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no mention in the transcript of any current or planned fundraising through debt or equity.
- The company is focusing on internal CAPEX of around Rs. 120-130 crore this year, primarily for capacity expansion and project modifications, funded through existing resources.
- No indications or discussions about raising fresh capital via equity or debt instruments were noted during the Q2 FY25 earnings call.
- The management appears confident about meeting growth and margin targets using their operational cash flows and existing funds.
- Emphasis is on optimizing capacity utilization, new product initiatives, and expanding export markets rather than seeking external funding.
See what Rossari Biotech management said on order book — free account, 30 seconds.
Capex plans
Yes- Ongoing CAPEX projects at Unitop and Dahej facilities with about Rs. 60 - Rs. 65 crore already spent.
- A similar amount expected to be spent over the next 6 months.
- Projects to be commissioned in Q3, Q4 of the current year and Q1 of next year.
- Total project budget enhanced by Rs. 18.25 crore, now up to Rs. 146.25 crore due to design modifications.
- Additional acquisition of 39,101 sqm land adjacent to Dahej facility for future expansion.
- These investments aimed at serving high-growth segments such as agrochemicals, home & personal care, and specialty chemicals.
- Expected asset turn of roughly 3x-4x from these investments.
- Establishment of Rossari Biotech Trading FZE in UAE for export market distribution and sales.
- Acquisition of 100% equity in Unistar Thai Company Limited, focusing on specialty chemical manufacturing.
Track Rossari Biotech — get its next earnings analysis in your feed
How does Rossari Biotech rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Rossari Biotech rank in Chemicals & Petrochemicals?
Compare Rossari Biotech against every Chemicals & Petrochemicals company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Rossari Biotech's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…